Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
mRNA-1975 · 1 trial · 1 indication
Solicited ARs were collected in an electronic diary (eDiary). Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered adverse events (AEs). Investigator reviewed whether the solicited AR was also to be recorded as an AE. A summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
Solicited ARs were collected in an eDiary. Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered AEs. Investigator reviewed whether the solicited AR was also to be recorded as an AE. A summary of SAEs and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
Solicited ARs were collected in an eDiary. Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered AEs. Investigator reviewed whether the solicited AR was also to be recorded as an AE. A summary of SAEs and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
A MAAE is an AE that led to an unscheduled visit to a healthcare practitioner. An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor were required. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
| Arm | Type | Description |
|---|---|---|
| mRNA-1975: Dose 1 | EXPERIMENTAL | Participants will receive 3 intramuscular (IM) injections of the mRNA-1975 vaccine at Dose Level 1 on Days 1, 57, and 169. |
| mRNA-1975: Dose 2 | EXPERIMENTAL | Participants will receive 3 IM injections of the mRNA-1975 vaccine at Dose level 2 on Days 1, 57, and 169. |
| mRNA-1975: Dose 3 | EXPERIMENTAL | Participants will receive 3 IM injections of the mRNA-1975 vaccine at Dose Level 3 on Days 1, 57, and 169. |
| mRNA-1975: Dose 4 | EXPERIMENTAL | Participants will receive 3 IM injections of the mRNA-1975 vaccine at Dose level 4 on Days 1, 57, and 169. |
| mRNA-1982: Dose 1 | EXPERIMENTAL | Participants will receive 3 IM injections of the mRNA-1982 vaccine at Dose Level 1 on Days 1, 57, and 169. |
| mRNA-1982: Dose 2 | EXPERIMENTAL | Participants will receive 3 IM injections of the mRNA-1982 vaccine at Dose Level 2 on Days 1, 57, and 169. |
| mRNA-1982: Dose 3 | EXPERIMENTAL | Participants will receive 3 IM injections of the mRNA-1982 vaccine at Dose level 3 on Days 1, 57, and 169. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive 3 IM injections of vaccine-matching placebo on Days 1, 57, and 169. |
| Name | Type | Description |
|---|---|---|
| mRNA-1975 | BIOLOGICAL | Dispersion delivered IM |
| mRNA-1982 | BIOLOGICAL | Dispersion delivered IM |
| Placebo | BIOLOGICAL | Solution delivered IM |
Inclusion Criteria: * Body mass index of 18 to 39 kilograms/square meter (inclusive) at the Screening Visit. * Participants of nonchildbearing potential may be enrolled in the study. * For female participants of childbearing potential: negative pregnancy test, adequate contraception or has abstaine...
Top 20 of 24 competitors
mRNA-1975 is an investigational messenger RNA (mRNA) vaccine being developed for the prevention of Lyme disease. It is designed to elicit an immune response against the bacterium that causes Lyme disease, which is transmitted through tick bites. The vaccine is currently in clinical development and has not been approved by regulatory authorities.
mRNA-1975 is being developed by Moderna, Inc., a biotechnology company publicly traded under the ticker symbol MRNA on the Nasdaq stock exchange. Moderna is known for its mRNA-based therapeutic and vaccine platform, and mRNA-1975 is one of its candidates targeting infectious diseases.
mRNA-1975 is in Phase 1 clinical development. A Phase 1 study has been completed, evaluating the safety and immunogenicity of the vaccine in healthy adults aged 18 through 70 years. The vaccine is investigational and has not yet received regulatory approval for use outside of clinical trials.
mRNA-1975 has been studied in a Phase 1 clinical trial with the identifier NCT05975099. This randomized, double-blind, placebo-controlled study assessed the safety and immunogenicity of mRNA-1975 and another Moderna Lyme disease vaccine candidate, mRNA-1982, in 807 participants in the United States. The trial has been completed.
No, mRNA-1975 and mRNA-1982 are distinct vaccine candidates developed by Moderna for Lyme disease. Both were evaluated together in the same Phase 1 clinical trial (NCT05975099), but they are separate investigational products with potentially different antigen designs or formulations. Each is being studied for its individual safety and immunogenicity profile.